Target intelligence / Profile preview

Sulfonylurea receptor 1 subunit of the KATP channel (SUR1)

Target
SUR1
Molecular classification
ATP-binding cassette (ABC) transporter family, Ion channel regulatory subunit, Membrane transporter (modulatory subunit), Receptor (for sulfonylureas), Other: part of the ATP-sensitive potassium channel complex
01

Overview

Sulfonylurea receptor 1 (SUR1) is the regulatory subunit of the pancreatic ATP-sensitive potassium channel (KATP channel), an octameric complex comprising four inward-rectifier potassium channel Kir6.2 subunits and four SUR1 subunits[1][2][6]. SUR1 belongs to the ATP-binding cassette (ABC) transporter family, but it does not transport a substrate; instead, it modulates the gating of the channel complex by sensing intracellular nucleotides and binding pharmacologic agents, such as sulfonylureas and channel openers[1][2]. In pancreatic β-cells, SUR1/Kir6.2 channels couple cellular energy status to insulin secretion, playing a central role in metabolic homeostasis[6]. Mutations in the ABCC8 gene encoding SUR1 cause disorders like congenital hyperinsulinism or neonatal diabetes. SUR1 is also expressed in cardiac and some neuronal tissues, where it contributes to cardiac protection under metabolic stress and possibly to pathologies if dysregulated[4][5].

Other names
ABCC8Sulfonylurea receptor 1SUR1ATP-binding cassette sub-family C member 8
02

Mechanism of action

Sulfonylureas and glinides: bind SUR1 and inhibit KATP channel activity, causing depolarization of the cell membrane and stimulating insulin release[6][4]. - Diazoxide: binds and opens KATP channels via SUR1, hyperpolarizing the membrane and inhibiting insulin release[4].

03

Biological functions

Regulation of insulin secretionCoupling of cellular metabolism to electrical activity (metabolic sensing)Control of membrane potentialModulation of cardiac protection under metabolic stressRegulation of vascular tone
04

Disease associations

Diabetes (particularly neonatal diabetes and congenital hyperinsulinism)Cardiovascular disease (myocardial ischemia/reperfusion injury)Other: channelopathies affecting metabolism and excitability
05

Safety considerations

Risk of hypoglycemia (with sulfonylurea therapy)Potential off-target effects in cardiac or neuronal tissue, particularly if aberrant SUR1 expression occursChannelopathies due to ABCC8 mutations can cause severe metabolic disease[6][4]
06

Interacting drugs

Glibenclamide (glyburide)

6 more in the full profile.

07

Biomarkers

ABCC8 gene mutations (for congenital hyperinsulinism or neonatal diabetes)KATP channel activity in β-cells (functional biomarker in diabetes diagnostics)

Beyond the preview

Go deeper on Sulfonylurea receptor 1 subunit of the KATP channel (SUR1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sulfonylurea receptor 1 subunit of the KATP channel (SUR1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call